All fellows are required to develop at least one clinical research protocol during their fellowship regardless of whether they intend to focus on clinical research or laboratory research. Fellows identify a mentor early in their first year.
Mentors guide fellows through the protocol development process that includes formulating a research plan, writing a letter of intent, securing funding, writing the protocol, and accruing and monitoring patients on the protocol. Fellows analyze and present the data and prepare and submit manuscript(s) for potential publication.
Possible Fellowship Projects include:
Since the Fellowship Projects Program began in July 2002, there have been:
Fellows present their research to the faculty at the annual Fall (2nd and 3rd Year Fellows) and Spring (1st Year Fellows) Research Symposia.
|Brian Hess, MD||A Phase I/II Study of ALT-803 in Patients with Relapsed/Refractory Indolent B-cell Non-Hodgkin Lymphoma in Conjunction with Rituximab|
|Jesse Keller, MD||A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma|
|Armin Rashidi, MD||Early Post-Transplant Abdominal CT to Predict the Risk of Acute GvHD|
|Peter Riedell, MD||A Multicenter Phase I Dose-Finding and Preliminary Efficacy Study of the Histone Deacetylase Inhibitor Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone for the Treatment of Adults with Relapsed/Refractory Aggressive Lymphomas|
|Andrea Teague, MD||Phase I/II Study Combining Tosedostat with Capecitabine in Patients with Advanced or Metastatic Pancreatic Adenocarcinoma|
|Amy Zhou, MD||Pilot Study of Pacritinib with Low Dose Decitabine in Patients with Intermediate High-Risk Myelofibrosis and MPN/MDS Syndromes|
|Kevin Chen, MD||A Phase II Study (PRO-TCCG) of Clinical Outcomes Using a Tailored Comprehensive Cancer Gene Set in Head and Neck Cancer|
|Matthew Christopher, MD, PhD||Primary Acute Myeloid Leukemia Cells with IDH1 or IDH2 Mutations Respond to a DOT1L Inhibitor In Vitro|
|Ashley Frith, MD||A Non-Inferiority Study of Doxorubicin with Dexrazoxane for the First Line Treatment of Advanced or Metastatic Soft Tissue Sarcoma|
|Angela Hirbe, MD, PhD||A Phase II Trial of Tumor Ablation in Metastatic Sarcoma Stable on Chemotherapy|
|Jeff Ward, MD, PhD||A Phase I Trial of Brentuximab Vedotin in Combination with Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma|
|Rusudan Hopman, MD||A Phase I and Randomized Phase II Study Testing the Safety and Efficacy of MK-3475 in Combination with MRI-Guided Laser Ablation in Recurrent Malignant Gliomas|
|Tom Regenbogen, MD||Phase II study with Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer|
|Ted Thomas, MD||Personalized Therapy for Esophagogastric Cancer using Thymidylate Synthase Genetic Markers|
|Andy Liao, MD||Phase II Study of Neratinib with or without Fulvestrant in HER2 Non-amplified but Mutated Metastatic Breast Cancer|
|Sid Devarakonda, MD||Role of Pacritinib in Patients with NSCLC Failing First Line Therapy with an EGFR Inhibitor|
|Lingling Du, MD||A Pilot Study of IDO Inhibitor Indoximod and Hyeracute®-Lung (HAL) Immunotherapy in Patients with Advanced Previously Treated Non-Small Cell Lung Cancer|
|Tanner Johanns, MD, PhD||A Phase I/II Study of PD-1 in Patients with Recurrent/Refractory Solid Tumors with Brain Metastasis|